162 related articles for article (PubMed ID: 36588796)
1. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.
Li K; Fan T; Shi Z; Jiang H
Anal Cell Pathol (Amst); 2022; 2022():9912254. PubMed ID: 36588796
[TBL] [Abstract][Full Text] [Related]
2. CDCA2 triggers in vivo and in vitro proliferation of hepatocellular carcinoma by activating the AKT/CCND1 signaling.
Li J; Chen Y; Wang X; Wang C
J BUON; 2021; 26(3):882-888. PubMed ID: 34268949
[TBL] [Abstract][Full Text] [Related]
3. CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo.
Feng Y; Qian W; Zhang Y; Peng W; Li J; Gu Q; Ji D; Zhang Z; Wang Q; Zhang D; Sun Y
BMC Cancer; 2019 Jun; 19(1):576. PubMed ID: 31196027
[TBL] [Abstract][Full Text] [Related]
4. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.
Wang J; Liu X; Chu H; Chen J
PeerJ; 2022; 10():e13535. PubMed ID: 35694386
[TBL] [Abstract][Full Text] [Related]
5. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
6. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
[No Abstract] [Full Text] [Related]
7. Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway.
Cai T; Bai J; Tan P; Huang Z; Liu C; Wu Z; Cheng Y; Li T; Chen Y; Ruan J; Gao L; DU Y; Fu W
Oncol Res; 2023; 31(5):805-817. PubMed ID: 37547758
[TBL] [Abstract][Full Text] [Related]
8. SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway.
Wang H; Chen M; Yang C; Hu H; Jiang Y; Yang F; Lv L
Arch Biochem Biophys; 2023 Jul; 743():109661. PubMed ID: 37268273
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Rab5a promotes hepatocellular carcinoma cell proliferation and invasion via FAK signaling pathway.
Geng D; Zhao W; Feng Y; Liu J
Tumour Biol; 2016 Mar; 37(3):3341-7. PubMed ID: 26443539
[TBL] [Abstract][Full Text] [Related]
10. E2F3/CDCA2 reduces radiosensitivity in gastric adenocarcinoma by activating PI3K/AKT pathway.
Gao J; Wang H; Qiu X; Tang J
Br J Radiol; 2023 Dec; 96(1152):20230477. PubMed ID: 37750838
[TBL] [Abstract][Full Text] [Related]
11. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
12. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
13. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
14. [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].
Shang L; Jiang W; Zhang J; Wu W
Nan Fang Yi Ke Da Xue Xue Bao; 2022 May; 42(5):665-672. PubMed ID: 35673909
[TBL] [Abstract][Full Text] [Related]
15. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
16. LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway.
Li W; Fu Q; Man W; Guo H; Yang P
Eur J Pharmacol; 2019 Apr; 849():106-114. PubMed ID: 30710550
[TBL] [Abstract][Full Text] [Related]
17. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma.
Wang S; Cao K; Liao Y; Zhang W; Zheng J; Li X; Huang M; Zhong Y; Hu X; Chen D; Wang Y
Oncogene; 2021 Jun; 40(25):4368-4383. PubMed ID: 34103686
[TBL] [Abstract][Full Text] [Related]
18. Cleavage stimulation factor 2 promotes malignant progression of liver hepatocellular carcinoma by activating phosphatidylinositol 3'-kinase/protein kinase B/mammalian target of rapamycin pathway.
Zhang MH; Liu J
Bioengineered; 2022 Apr; 13(4):10047-10060. PubMed ID: 35412944
[TBL] [Abstract][Full Text] [Related]
19. Equilibrative nucleoside transporter 3 promotes the progression of hepatocellular carcinoma by regulating the AKT/mTOR signaling pathway.
Qin P; Yan J; Huang H; Wang Q; Li M; Zhang Y; Wang J; Jiang T; Zhang X; Zhou Y
Int J Biol Macromol; 2023 Jun; 241():124323. PubMed ID: 37023875
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA‑9‑5p downregulates Klf4 and influences the progression of hepatocellular carcinoma via the AKT signaling pathway.
Dong X; Wang F; Xue Y; Lin Z; Song W; Yang N; Li Q
Int J Mol Med; 2019 Mar; 43(3):1417-1429. PubMed ID: 30664155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
